Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Is BioSante Next In The Biotech Buyout Binge?
Nov 14, 2008 02:32 PM
- Is It Time To Invest In Pharmaceuticals?
Aug 18, 2008 08:42 AM
- FDA Calendar: Buy CV Therapeutics and Sell Noven Pharma
Aug 07, 2008 02:05 AM
- UPDATE: Shire Recalls Some Daytrana Hyperactivity Patches
Jun 09, 2008 11:30 AM
- UPDATE: Shire Recalls Some Daytrana Hyperactivity Patches
Jun 09, 2008 11:30 AM
- NASDAQ Technical Picture - Hanging Man to End Bullish Week
May 19, 2008 01:56 AM
- Noven Appoints Michael D. Price Chief Financial Officer
Nov 15, 2007 05:29 PM
- Oncology Market To Grow At Twice The Pace of Pharma Market
Nov 14, 2007 10:58 AM
- UPDATE: Acambis Cuts Fiscal Year Loss,Focus On Traditional Vaccines
Mar 15, 2007 08:12 AM
- Hospira Bids $2 Billion For Mayne Pharma, May Face Rivals
Sep 21, 2006 07:46 AM
- Noven Announces 2008 Third Quarter Financial Results
Nov 06, 2008 08:25 AM
- Noven Announces 2008 Third Quarter Earnings Release Date
Oct 30, 2008 04:45 PM
- Noven Names Peter Amanatides as Vice President - Quality Assurance & Quality Control
Sep 29, 2008 08:33 AM
- Noven to Present at UBS Global Life Sciences Conference
Sep 11, 2008 04:01 PM
- Noven Provides Update on Daytrana(R) Methylphenidate Transdermal System
Aug 25, 2008 08:34 AM
- Noven Signs License and Supply Agreements with Procter & Gamble Pharmaceuticals for Patches to Treat HSDD
Aug 20, 2008 05:01 PM
- Noven Announces 2008 Second Quarter Financial Results
Aug 06, 2008 08:38 AM
- Noven Announces Triggering of $25 Million Daytrana(R) Sales Milestone
Aug 04, 2008 08:56 AM
- Noven Announces 2008 Second Quarter Earnings Release Date
Aug 01, 2008 04:23 PM
- Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
Jul 30, 2008 08:25 AM
- Form 4 PRICE MICHAEL DENNIS For: Nov 21 (10K)
Nov 25, 2008 08:57 AM
- Form 4 Brandt Peter C. For: Nov 21 (10K)
Nov 24, 2008 04:46 PM
- Form 4 Venditti Anthony For: Nov 18 (10K)
Nov 20, 2008 05:17 PM
- Form 4 Lippman Joel For: Nov 18 (10K)
Nov 20, 2008 05:14 PM
- Form 4 DINH STEVEN M For: Nov 18 (10K)
Nov 20, 2008 05:14 PM
- Form 4 Gilbert Richard P. For: Nov 18 (10K)
Nov 20, 2008 05:10 PM
- Form 4 PRICE MICHAEL DENNIS For: Nov 18 (10K)
Nov 20, 2008 05:05 PM
- Form 4 NOVEN PHARMACEUTICALS For: Oct 29 Filed by: Goffe Andrew J. (10K)
Oct 31, 2008 06:30 PM
- Form 4 NOVEN PHARMACEUTICALS For: Aug 29 Filed by: Brandt Peter C. (10K)
Sep 02, 2008 06:24 PM
- Form 4 NOVEN PHARMACEUTICALS For: Jul 14 Filed by: Lippman Joel (10K)
Jul 15, 2008 05:01 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
NOVN
|
Compare to S&P
|
| YTD |
-16.35 %
|
-0.01 %
|
| 4 Weeks |
2.93 %
|
21.96 %
|
| 12 Weeks |
-4.99 %
|
37.06 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 33.33 %
|
|
EPS Growth in Last Year: -20.00 %
|
|
Sales Growth in Last Quarter: 4.48 %
|
|
Sales Growth in Last Quarter: 17.83 %
|
|
|
